SMC Update - February 2016
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Fulvestrant (Faslodex®) has been accepted for use in he treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen. This is a re-submission assessed under the end of life process and takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of fulvestrant. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Guanfacine (Intuniv®) has been accepted for use in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Ulipristal (Esmya®) has been accepted for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « Drug Safety Update - January 2016 | Health Protection Guidance - Zika virus » |
Leave a Comment